Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SORD | Q00796 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464639 | 0.84 | KDM4E (0.49) | KDM4EHSD17B10ALDH1A1TSHRGAA | |
| SCHEMBL15107946 | 0.79 | SORD (0.45) | KDM4EHSD17B10HPGDNPSR1USP2 | |
| SCHEMBL13033928 | 0.79 | CASP1 (0.47) | KDM4EHPGDUSP2ALDH1A1SORD | |
| SCHEMBL27681034 | 0.78 | RBP4 (0.56) | KDM4EHSD17B10HPGDNPSR1USP2 | |
| SCHEMBL5457627 | 0.75 | ALDH1A1 (0.40) | KDM4EHSD17B10ALDH1A1SORD | |
| SCHEMBL15161604 | 0.72 | KDM4E (0.55) | KDM4EHSD17B10HPGDNPSR1USP2 | |
| SCHEMBL1103982 | 0.70 | MAPK8 (0.47) | KDM4EPIK3CAMTOR | |
| SCHEMBL13034556 | 0.70 | KDM4E (0.65) | KDM4EHSD17B10HPGDNPSR1USP2 | |
| SCHEMBL865813 | 0.69 | PDE10A (0.44) | KDM4EHSD17B10HPGDALDH1A1PIK3CA | |
| SCHEMBL23425939 | 0.68 | HRH3 (0.45) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ARAF, BRAF, RAF1 | KDM4E 521/4885HSD17B10 4741/4885HPGD 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.